Fortune columnist and former head of the FDIC Sheila Bair discusses the ouster of Citi CEO Vikram Pandit.
Follow this link: Sheila Bair: "I’m sure Vikram still blames me"
The Top Penny Stocks newsletter for active penny stocks investors looking for penny stocks and pink sheet stocks
Richemont chairman Johann Rupert to take 'grey gap... Billionaire 62-year-old to take 12 months off from Cartier and Montblanc luxury goods groupRichemont's chairman and founder Johann Rupert is to take a year off from September, leaving management of the...
Cambodia: aftermath of fatal shoe factory collapse... Workers clear rubble following the collapse of a shoe factory in Kampong Speu, Cambodia, on Thursday
Spate of recent shock departures by 50-something CEOs While the rising financial rewards of running a modern multinational have been well publicised, executive recruiters say the pressures of the job have also been ratcheted upOn approaching his 60th birthday...
UK Uncut loses legal challenge over Goldman Sachs tax... While judge agreed the deal was 'not a glorious episode in the history of the Revenue', he ruled it was not unlawfulCampaign group UK Uncut Legal Action has lost its high court challenge over the legality...
Eurozone crisis live: Japan's strong growth figures... PM Shinzo Abe's stimulus package could generate feelgood factor needed to end two decades of stagnant growthPhillip Inman
Fortune columnist and former head of the FDIC Sheila Bair discusses the ouster of Citi CEO Vikram Pandit.
Follow this link: Sheila Bair: "I’m sure Vikram still blames me"
Senior columnist Adam Feuerstein says the ASCO Cancer Conference is the next big thing in biotech.
See the rest here: The Next Big Thing In Biotech: ASCO Conference
Category : Stocks
Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.
Go here to see the original: The Next Big Thing in Biotech: Pfizer
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
Read the original: The Next Big Thing in Biotech: M&A
Category : World News
As the debate over whether to limit tax relief on charitable donations rumbles on, Polly Toynbee, writer, commentator and Guardian columnist, and John Low, chief executive of Charities Aid Foundation, debate the arguments in favour of the policy.
Read the original here: AUDIO: ‘Pay your taxes before charity’
Category : Stocks
Adam Feuerstein, senior columnist for TheStreet, explains why Alexza Pharmaceuticals is the next big thing in biotech.
See more here: The Next Big Thing in Biotech: Alexza
Category : Business
Are we facing a crisis of democracy? Guardian columnist Jonathan Freedland chairs a debate at the Guardian Open Weekend between David Miliband, Jeffrey Sachs and Ngaire Woods
Read more here: David Miliband, Jeffrey Sachs and Ngaire Woods: watch the debate in full – video
Senior columnist Adam Feuerstein explains why Vivus is the next big thing in biotech.
See the original post: The Next Big Thing in Biotech: Vivus
Senior columnist Adam Feuerstein explains the importance of three FDA drug approval decisions.
Read the original here: The Next Big Thing in Biotech: FDA Decisions

This week on The House, guest-host Alison Crawford brings you the latest developments in the robocall affair with CBC Senior Political Correspondent Terry Milewski and John Ivison, political columnist for The National Post.
Here is the original post: Did Pierre Poutine’s robocalls go beyond Guelph?